Traws Pharma (TRAW) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing novel therapies for respiratory viral diseases and certain cancers.

• Pipeline includes investigational antivirals for influenza, COVID-19, and oncology candidates.

• Shifted focus to antivirals after a merger in April 2024, expanding from oncology to infectious diseases.

Financial performance and metrics

• Recurring losses from operations since inception raise substantial doubt about ability to continue as a going concern.

• As of June 29, 2026, market value of outstanding common stock held by non-affiliates was approximately $31.7 million.

• Sold approximately $4.2 million of securities in the prior 12 months under Form S-3.

Use of proceeds and capital allocation

• Net proceeds will fund clinical and preclinical program development, R&D, general corporate purposes, and potential acquisitions.

• Pending use, proceeds may be invested in investment grade interest-bearing securities.